Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
Participants received either oral fenebrutinib twice daily or oral teriflunomide once daily for at least 96 weeks.
Clinical Trials
Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy
Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial
Gossamer Bio reports topline Phase III PROSERA outcomes for PAH
J&J reports long-term QUASAR data for Tremfya in ulcerative colitis
Serina Therapeutics enrols first patient for SER-252 trial
